<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837274</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2008-0164F</org_study_id>
    <nct_id>NCT04837274</nct_id>
  </id_info>
  <brief_title>Anderson Study 1 - Tart Cherry Study</brief_title>
  <acronym>AS1</acronym>
  <official_title>Effects Of Tary Cherry Ingestion On Food-Induced Serum Uric Acid Elevation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas A&amp;M University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anderson Global Group, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas A&amp;M University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine if tart cherry reduces food-induced elevations in&#xD;
      serum uric acid.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gout is a painful form of arthritis that is caused by hyperuricemia (high uric acid levels)&#xD;
      that form crystals in the joints. Ingestion of food and/or beverages containing high purine&#xD;
      levels (e.g., beef, game meats, liver, shellfish, herring, mackerel, anchovies, sardines,&#xD;
      mushrooms, dried beans and peas, sweetbreads, excessive alcohol, etc.) increase uric acid&#xD;
      levels and thereby can complicate the management of uric acid levels in individuals with&#xD;
      hyeruricemia and/or gout. Prior research has shown that ingestion of a chrysanthemum flower&#xD;
      oil containing a high level of polyphenols significantly reduced the uricemic response to&#xD;
      ingesting a meal high in purines. Additionally, black cherry and grape juice extracts are&#xD;
      purported to have uric acid lowering properties. We have previoulsy reported that tart cherry&#xD;
      powder, another naturally occuriring source of phlyphenols, lessens exercise-induced&#xD;
      inflammation. This study will examine if tart cherry can also reduce the uricemic response to&#xD;
      ingesting a high purine containing meal. If so, this may provide another dietary approach to&#xD;
      help individuals manage their uric acid levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double (Participant, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Uric Acid Changes</measure>
    <time_frame>Measured at baseline (prior to supplementation (Pre)), and after 60, 120, 180 and 240 minutes</time_frame>
    <description>Serum Uric Acid changes to ingesting a high purine containing meal,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effects Assessment</measure>
    <time_frame>Measured at baseline prior to supplementation (Pre)</time_frame>
    <description>Abdominal Side Effects Assessment on a 5 point likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects Assessment</measure>
    <time_frame>Measured after 240 minutes (Post)</time_frame>
    <description>Abdominal Side Effects Assessment on a 5 point likert scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Health Services Research</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dextrose (480 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tart Cherry (480 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dextrose (480 mg)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Active</intervention_name>
    <description>Tary Cherry (480 mg)</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  They are healthy males or females ages 30 to 60 years with fasting serum uric acid&#xD;
             (UA) levels between 5.5 and 8.0 mg/dl obtained during the familiarization/screening&#xD;
             visit;&#xD;
&#xD;
          -  They have a willingness to provide voluntary, written, informed consent to participate&#xD;
             in the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  They take prescription (Rx) medications (i.e., Uloric, Krystexxa, etc.) or dietary&#xD;
             supplements known to have UA-reducing activity (i.e., black cherry, devil's claw,&#xD;
             grape seed extracts, etc.);&#xD;
&#xD;
          -  They have regular diseases requiring regular prescription (Rx) medications (birth&#xD;
             control is allowed);&#xD;
&#xD;
          -  They have abnormal/out of range values in laboratory tests determined at the&#xD;
             familiarization/screening visit;&#xD;
&#xD;
          -  They have an allergy to tart cherry or immunoglobulin E;&#xD;
&#xD;
          -  They are pregnant, trying to become pregnant or breastfeeding;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard B Kreider, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas A&amp;M University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard B Kreider, PhD</last_name>
    <phone>9794581498</phone>
    <email>rbkreider@tamu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Exercise &amp; Sport Nutrition Lab - Human Clinical Research Facility</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard B Kreider, PhD</last_name>
      <phone>979-458-1498</phone>
      <email>rbkreider@tamu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chris Rasmussen, MS</last_name>
      <phone>9794581741</phone>
      <email>crasmussen@tamu.edy</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas A&amp;M University</investigator_affiliation>
    <investigator_full_name>Richard B. Kreider</investigator_full_name>
    <investigator_title>Executive Director, Human Clinical Research Facility</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

